Investing.com - NeoGenomics (NASDAQ: NEO) reported second quarter EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $165M versus the consensus estimate of $161.82M.
Guidance
NeoGenomics sees FY 2024 revenue of $655.00M-$667.00M versus the analyst consensus of $655.60M.
NeoGenomics's stock price closed at $14.64. It is down -0.54% in the last 3 months and down -15.18% in the last 12 months.
NeoGenomics saw 9 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See NeoGenomics's stock price’s past reactions to earnings here.
According to InvestingPro, NeoGenomics's Financial Health score is "good performance".
Check out NeoGenomics's recent earnings performance, and NeoGenomics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar